Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients
暂无分享,去创建一个
T. Matsushima | D. Takahari | T. Ichimura | K. Yamaguchi | T. Wakatsuki | M. Ozaka | E. Shinozaki | M. Ogura | M. Suenaga | N. Mizunuma | I. Nakayama | K. Chin